Ternary Therapeutics

In pharmacology, there are therapeutic targets that seem unreachable: proteins that contribute to serious diseases but lack a pocket where a conventional drug can bind. These so-called undruggable targets have for decades marked the boundary between what medicine can treat and what it cannot. Ternary Therapeutics, a London-based biotech, is building the tools to cross that boundary. The company uses artificial intelligence to design molecular glues — small molecules capable of inducing interactions between proteins that would not normally bind, creating ternary protein complexes with novel therapeutic properties. This technology allows precise targeting of proteins involved in cancer and other serious diseases that conventional drugs cannot effectively inhibit or degrade. AI accelerates the molecular design phase, reducing the time and cost required to identify promising candidates to advance into testing. Ternary Therapeutics is in the preclinical stage, meaning therapeutic programs are still in development and commercial revenues are not yet present. This is the normal reality for a fundamental research biotech: the path from discovery to pharmaceutical approval takes years and significant investment, but the potential value is proportional to the difficulty of the problem being addressed. The path to monetization involves partnerships with large pharmaceutical companies interested in accessing the technology and development programs: upfront payments, milestones upon achieving clinical objectives, royalties on future sales, and possible territorial rights assignments. This model is standard in the biotech sector and allows early-stage companies to fund research through pipeline value without waiting for commercial approval. The molecular glue field is attracting growing attention following several notable clinical validations, and the ability to combine this technology with AI to accelerate discovery positions Ternary Therapeutics in a space with high scientific and industrial potential.